JP6936815B2 - Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 - Google Patents
Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 Download PDFInfo
- Publication number
- JP6936815B2 JP6936815B2 JP2018562331A JP2018562331A JP6936815B2 JP 6936815 B2 JP6936815 B2 JP 6936815B2 JP 2018562331 A JP2018562331 A JP 2018562331A JP 2018562331 A JP2018562331 A JP 2018562331A JP 6936815 B2 JP6936815 B2 JP 6936815B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- het
- substituted
- cycloalkyl
- atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- GPTUGFBGLQCERR-UHFFFAOYSA-O CC(C)[n](c(C(NC)=O)c1)nc1[N+](O)=O Chemical compound CC(C)[n](c(C(NC)=O)c1)nc1[N+](O)=O GPTUGFBGLQCERR-UHFFFAOYSA-O 0.000 description 1
- ZLOMRMTVSFENBP-UHFFFAOYSA-O CC(C)[n](c([N+](O)=O)c1)nc1C(NC)=O Chemical compound CC(C)[n](c([N+](O)=O)c1)nc1C(NC)=O ZLOMRMTVSFENBP-UHFFFAOYSA-O 0.000 description 1
- UPTIQMLLFYHQPD-UHFFFAOYSA-N CN(C1)C2C1CCNC2 Chemical compound CN(C1)C2C1CCNC2 UPTIQMLLFYHQPD-UHFFFAOYSA-N 0.000 description 1
- XKPWQAUVZANBIU-UHFFFAOYSA-N CN(C1)C2C1CNCC2 Chemical compound CN(C1)C2C1CNCC2 XKPWQAUVZANBIU-UHFFFAOYSA-N 0.000 description 1
- JEMUNAIYDRDREC-UHFFFAOYSA-N CN(C=C1[NH+]([O-])O)NC1=O Chemical compound CN(C=C1[NH+]([O-])O)NC1=O JEMUNAIYDRDREC-UHFFFAOYSA-N 0.000 description 1
- 0 CN(CC(*)(*)c1cc(-c2c(*)cnc([N-]*)n2)c2)c1c2C#N Chemical compound CN(CC(*)(*)c1cc(-c2c(*)cnc([N-]*)n2)c2)c1c2C#N 0.000 description 1
- OBAXRSXTJUNZRQ-UHFFFAOYSA-N CN1CC(C2)C2C1 Chemical compound CN1CC(C2)C2C1 OBAXRSXTJUNZRQ-UHFFFAOYSA-N 0.000 description 1
- YQURLNGUWNDBIR-UHFFFAOYSA-N CN1CC(CNC2)C2C1 Chemical compound CN1CC(CNC2)C2C1 YQURLNGUWNDBIR-UHFFFAOYSA-N 0.000 description 1
- YTKHEIJTGJUQFD-UHFFFAOYSA-O CO[N+](c1n[n](C2CCCC2)c(C(O)=O)c1)=O Chemical compound CO[N+](c1n[n](C2CCCC2)c(C(O)=O)c1)=O YTKHEIJTGJUQFD-UHFFFAOYSA-O 0.000 description 1
- RDZMEKBZANEQDL-UHFFFAOYSA-N C[NH+](c1cc(C(O)=O)n[n]1C1CCCC1)[O-] Chemical compound C[NH+](c1cc(C(O)=O)n[n]1C1CCCC1)[O-] RDZMEKBZANEQDL-UHFFFAOYSA-N 0.000 description 1
- YNTAYZIFUBFSNU-UHFFFAOYSA-N Cc1n[n](CC2CCN(CC(N(C)C)=O)CC2)c([N+]([O-])=O)c1 Chemical compound Cc1n[n](CC2CCN(CC(N(C)C)=O)CC2)c([N+]([O-])=O)c1 YNTAYZIFUBFSNU-UHFFFAOYSA-N 0.000 description 1
- KKGKHOSFZZIYEK-UHFFFAOYSA-O O=[NH+]c1c[nH]nc1OC1CC1 Chemical compound O=[NH+]c1c[nH]nc1OC1CC1 KKGKHOSFZZIYEK-UHFFFAOYSA-O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16177104.3 | 2016-06-30 | ||
| EP16177104 | 2016-06-30 | ||
| PCT/EP2017/066120 WO2018002217A1 (en) | 2016-06-30 | 2017-06-29 | Heteroaromatic derivatives as nik inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521097A JP2019521097A (ja) | 2019-07-25 |
| JP2019521097A5 JP2019521097A5 (OSRAM) | 2020-08-06 |
| JP6936815B2 true JP6936815B2 (ja) | 2021-09-22 |
Family
ID=56296645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562331A Active JP6936815B2 (ja) | 2016-06-30 | 2017-06-29 | Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11136311B2 (OSRAM) |
| EP (1) | EP3478675B1 (OSRAM) |
| JP (1) | JP6936815B2 (OSRAM) |
| KR (1) | KR102517352B1 (OSRAM) |
| CN (1) | CN109641882B (OSRAM) |
| AU (1) | AU2017289315B2 (OSRAM) |
| CA (1) | CA3027416A1 (OSRAM) |
| ES (1) | ES2805976T3 (OSRAM) |
| WO (1) | WO2018002217A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3012031C (en) | 2016-01-22 | 2024-03-26 | Janssen Pharmaceutica Nv | 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors |
| US11180487B2 (en) | 2016-01-22 | 2021-11-23 | Janssen Pharmaceutica Nv | Substituted cyanoindoline derivatives as NIK inhibitors |
| WO2018002219A1 (en) | 2016-06-30 | 2018-01-04 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as nik inhibitors |
| JP6936815B2 (ja) | 2016-06-30 | 2021-09-22 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 |
| JP7301958B2 (ja) | 2018-05-25 | 2023-07-03 | オンコキューブ セラピューティクス エルエルシー | 新規な抗がん薬候補としての非常に強力なｔａｃｃ３阻害剤 |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| AU2019203034B1 (en) * | 2018-07-25 | 2019-09-26 | Hanmi Pharm. Co., Ltd. | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same |
| PE20212153A1 (es) | 2019-02-22 | 2021-11-09 | Hanmi Pharm Ind Co Ltd | Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda |
| MX2021014679A (es) | 2019-05-31 | 2022-04-06 | Janssen Pharmaceutica Nv | Inhibidores de molécula pequeña de quinasa inductora de nf-kb. |
| WO2020258006A1 (en) | 2019-06-25 | 2020-12-30 | Inventisbio Shanghai Ltd. | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof |
| KR20210002015A (ko) | 2019-06-27 | 2021-01-06 | 한미약품 주식회사 | Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물 |
| CN117460724A (zh) * | 2021-04-12 | 2024-01-26 | A2A制药有限公司 | 用于治疗癌症的组合物和方法 |
| KR20250005157A (ko) | 2022-03-24 | 2025-01-09 | 에이2에이 파마수티칼스, 잉크. | 암 치료를 위한 조성물 및 방법 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2306671T3 (es) | 1999-10-07 | 2008-11-16 | Amgen Inc. | Inhibidores de triazina quinasa. |
| AU2001237041B9 (en) | 2000-02-17 | 2005-07-28 | Amgen Inc. | Kinase inhibitors |
| CA2401778C (en) | 2000-02-29 | 2010-12-21 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| CA2441733A1 (en) * | 2001-03-29 | 2002-10-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| HUP0402352A2 (hu) | 2001-06-19 | 2005-02-28 | Bristol-Myers Squibb Co. | Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| AU2009263037B2 (en) * | 2008-06-26 | 2011-10-06 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
| EP2361248B1 (en) | 2008-06-27 | 2018-09-19 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| US20110183975A1 (en) * | 2008-10-07 | 2011-07-28 | Yasuhiro Goto | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| ES2608670T3 (es) | 2009-08-17 | 2017-04-12 | Memorial Sloan-Kettering Cancer Center | Derivados de 2-(pirimidin-5-il)-tiopirimidina como moduladores de Hsp70 y Hsc70 para el tratamiento de trastornos proliferativos |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| PT2598483T (pt) | 2010-07-29 | 2020-10-12 | Rigel Pharmaceuticals Inc | Compostos heterocíclicos de ativação de ampk e métodos de utilização dos mesmos |
| CN103732067A (zh) | 2011-04-12 | 2014-04-16 | 美国阿尔茨海默病研究所公司 | 化合物，组合物及它们的治疗用途 |
| TWI663166B (zh) | 2013-04-24 | 2019-06-21 | 健生藥品公司 | 新化合物 |
| CA2922657C (en) | 2013-08-30 | 2022-04-12 | Ptc Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
| TWI704146B (zh) * | 2013-09-26 | 2020-09-11 | 比利時商健生藥品公司 | 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物 |
| TWI627173B (zh) | 2013-09-26 | 2018-06-21 | 比利時商健生藥品公司 | 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物 |
| EP3489232A3 (en) | 2014-04-04 | 2019-07-31 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| JP2017520526A (ja) | 2014-05-22 | 2017-07-27 | ザ・ユニバーシティ・オブ・シドニー | オメガ−３類似体 |
| WO2016022645A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| CN106715419A (zh) * | 2014-09-26 | 2017-05-24 | 吉利德科学公司 | 用作tank‑结合激酶抑制剂化合物的氨基三嗪衍生物 |
| CN106928216A (zh) | 2015-12-31 | 2017-07-07 | 中国科学院上海药物研究所 | 具有erk激酶抑制活性的化合物、其制备方法和用途 |
| US11180487B2 (en) | 2016-01-22 | 2021-11-23 | Janssen Pharmaceutica Nv | Substituted cyanoindoline derivatives as NIK inhibitors |
| CA3012031C (en) | 2016-01-22 | 2024-03-26 | Janssen Pharmaceutica Nv | 6-membered heteroaromatic substituted cyanoindoline derivatives as nik inhibitors |
| EP3429591B1 (en) | 2016-03-16 | 2023-03-15 | Kura Oncology, Inc. | Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use |
| JP6936815B2 (ja) | 2016-06-30 | 2021-09-22 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 |
| WO2018002219A1 (en) | 2016-06-30 | 2018-01-04 | Janssen Pharmaceutica Nv | Cyanoindoline derivatives as nik inhibitors |
-
2017
- 2017-06-29 JP JP2018562331A patent/JP6936815B2/ja active Active
- 2017-06-29 AU AU2017289315A patent/AU2017289315B2/en active Active
- 2017-06-29 CA CA3027416A patent/CA3027416A1/en active Pending
- 2017-06-29 WO PCT/EP2017/066120 patent/WO2018002217A1/en not_active Ceased
- 2017-06-29 ES ES17739902T patent/ES2805976T3/es active Active
- 2017-06-29 US US16/309,059 patent/US11136311B2/en active Active
- 2017-06-29 CN CN201780053583.6A patent/CN109641882B/zh active Active
- 2017-06-29 KR KR1020197002588A patent/KR102517352B1/ko active Active
- 2017-06-29 EP EP17739902.9A patent/EP3478675B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017289315A1 (en) | 2019-01-24 |
| CN109641882B (zh) | 2022-10-28 |
| KR20190025644A (ko) | 2019-03-11 |
| US11136311B2 (en) | 2021-10-05 |
| JP2019521097A (ja) | 2019-07-25 |
| AU2017289315B2 (en) | 2021-04-01 |
| EP3478675A1 (en) | 2019-05-08 |
| WO2018002217A1 (en) | 2018-01-04 |
| ES2805976T3 (es) | 2021-02-16 |
| KR102517352B1 (ko) | 2023-03-31 |
| CA3027416A1 (en) | 2018-01-04 |
| EP3478675B1 (en) | 2020-04-22 |
| US20190359598A1 (en) | 2019-11-28 |
| CN109641882A (zh) | 2019-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6936815B2 (ja) | Ｎｉｋ阻害剤としてのヘテロ芳香族誘導体 | |
| KR102815634B1 (ko) | 면역조절제로서 복소환형 화합물 | |
| JP6910359B2 (ja) | Ｎｉｋ阻害剤としての新たな置換されたシアノインドリン誘導体 | |
| JP6916796B2 (ja) | Ｎｉｋ阻害剤としての新たな６員のヘテロ芳香族置換シアノインドリン誘導体 | |
| JP6936814B2 (ja) | Ｎｉｋ阻害剤としてのシアノインドリン誘導体 | |
| JP6603713B2 (ja) | Ｎｉｋ阻害剤としての新規のチエノピリミジン誘導体 | |
| KR102662373B1 (ko) | Nik 억제제로서의 신규 치환 아자인돌린 유도체 | |
| RU2780577C2 (ru) | Новые замещенные производные азаиндолина в качестве ингибиторов nik | |
| HK1261385A1 (en) | New substituted cyanoindoline derivatives as nik inhibitors | |
| HK1261385B (en) | New substituted cyanoindoline derivatives as nik inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190109 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20200601 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200625 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200625 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20200625 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210415 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210427 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210701 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210810 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210827 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6936815 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |